β 3 ‐adrenoceptor agonism exerts lung protection in a rat model of bronchopulmonary dysplasia
British Journal of Pharmacology · 2026
DOI: 10.1111/bph.70333 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Pharmacology, 2026. Verfasst von Alessandro Pini und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. Hauptthemen laut MEDLINE: Bronchopulmonary Dysplasia, Adrenergic beta-3 Receptor Agonists, Lung, Ethanolamines. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of University and Research, European Union, NextGenerationEU, Meyer Foundation.
Abstract (Originalsprache)
Absract Background and Purpose Bronchopulmonary dysplasia (BPD) affects premature newborns, particularly those receiving supplemental oxygen therapy. Exposure of underdeveloped lungs to oxygen levels higher than the intrauterine environment causes oxidative stress, impairing alveolarisation, vascularisation and causing fibrosis. The β 3 ‐adrenoceptor could represent a promising target for BPD treatment because of its oxygen‐dependent regulation, ability to reduce oxidative stress and protection against intestinal hyperoxia‐induced damage. Experimental Approach In this study, neonatal rat pups were reared under hyperoxia for 2 weeks to induce a BPD‐like disease and treated with the β 3 ‐adrenoceptor agonist BRL37344 (1, 3 or 6 mg kg −1 ). Key Results Through oxidative stress, hyperoxia decreases pulmonary volume, impairs alveolarisation and vascularisation, and causes fibrosis and type II pneumocyte hyperplasia, thereby reducing survival rates. BRL37344 at 3 mg kg −1 counteracted these alterations, doubling survival rates. Conclusions and Implications Our findings demonstrate a new role for β 3 ‐adrenoceptors in protecting the lungs from hyperoxic injury, suggesting its pharmacological activation as a strategy for treating Bronchopulmonary dysplasia of prematurity and, possibly, other lung fibrosis‐related disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
- Unit of Translational and Precision Medicine, Meyer Children's Hospital IRCCS, Florence, Italy.
- Department of Chemistry and Industrial Chemistry, University of Pisa, Pisa, Italy.
- National Research Council-National Institute of Optics (CNR-INO), Sesto Fiorentino, Italy.
- Neonatology and Neonatal Intensive Care Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Förderung
- Italian Ministry of University and Research
- European Union, NextGenerationEU
- Meyer Foundation
- Intesa San Paolo
Zitieren
APA
Pini, A., Nardini, P., Zizi, V., Molino, M., Calvani, M., Carrozzo, F., Amato, R., Guasti, D., Biagini, D., di Francesco, F., Silvestri, L., Franceschini, A., Bani, D., Imbimbo, E., & Filippi, L. (2026). β 3 ‐adrenoceptor agonism exerts lung protection in a rat model of bronchopulmonary dysplasia. British Journal of Pharmacology. https://doi.org/10.1111/bph.70333
Vancouver
Pini A, Nardini P, Zizi V, Molino M, Calvani M, Carrozzo F, et al. β 3 ‐adrenoceptor agonism exerts lung protection in a rat model of bronchopulmonary dysplasia. British Journal of Pharmacology. 2026. doi:10.1111/bph.70333
BibTeX
@article{Pini2026,
author = {Pini, Alessandro and Nardini, Patrizia and Zizi, Virginia and Molino, Marta and Calvani, Maura and Carrozzo, Francesco and Amato, Rachele and Guasti, Daniele and Biagini, Denise and di Francesco, Fabio and Silvestri, Ludovico and Franceschini, Alessandra and Bani, Daniele and Imbimbo, Elisa and Filippi, Luca},
title = {β 3 ‐adrenoceptor agonism exerts lung protection in a rat model of bronchopulmonary dysplasia},
journal = {British Journal of Pharmacology},
year = {2026},
doi = {10.1111/bph.70333}
}
EUVIMED